Equitable Trust Co. Acquires 7,154 Shares of Edwards Lifesciences Co. (NYSE:EW)

Equitable Trust Co. increased its holdings in Edwards Lifesciences Co. (NYSE:EW) by 10.9% in the 4th quarter, according to its most recent filing with the SEC. The institutional investor owned 73,042 shares of the medical research company’s stock after buying an additional 7,154 shares during the quarter. Equitable Trust Co.’s holdings in Edwards Lifesciences were worth $5,407,000 at the end of the most recent reporting period.

Other large investors also recently bought and sold shares of the company. FSA Wealth Management LLC bought a new stake in shares of Edwards Lifesciences during the 3rd quarter valued at about $30,000. Migdal Insurance & Financial Holdings Ltd. bought a new stake in shares of Edwards Lifesciences during the 4th quarter valued at about $30,000. Prospera Private Wealth LLC bought a new stake in shares of Edwards Lifesciences during the 3rd quarter valued at about $32,000. Avior Wealth Management LLC grew its stake in shares of Edwards Lifesciences by 138.7% during the 3rd quarter. Avior Wealth Management LLC now owns 530 shares of the medical research company’s stock valued at $35,000 after purchasing an additional 308 shares during the period. Finally, JFS Wealth Advisors LLC grew its stake in shares of Edwards Lifesciences by 31.1% during the 3rd quarter. JFS Wealth Advisors LLC now owns 700 shares of the medical research company’s stock valued at $46,000 after purchasing an additional 166 shares during the period. 79.46% of the stock is currently owned by institutional investors.

Insiders Place Their Bets

In other Edwards Lifesciences news, VP Donald E. Bobo, Jr. sold 5,000 shares of the stock in a transaction that occurred on Wednesday, November 13th. The shares were sold at an average price of $65.57, for a total transaction of $327,850.00. Following the transaction, the vice president now owns 46,936 shares in the company, valued at $3,077,593.52. This represents a 9.63 % decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, VP Daniel J. Lippis sold 2,500 shares of the stock in a transaction that occurred on Monday, December 16th. The stock was sold at an average price of $74.08, for a total transaction of $185,200.00. Following the transaction, the vice president now owns 23,189 shares in the company, valued at approximately $1,717,841.12. The trade was a 9.73 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold 8,000 shares of company stock valued at $547,430 in the last three months. 1.29% of the stock is currently owned by corporate insiders.

Analysts Set New Price Targets

A number of research firms have recently weighed in on EW. Wolfe Research cut Edwards Lifesciences from a “peer perform” rating to an “underperform” rating and set a $60.00 price objective on the stock. in a research report on Thursday, January 16th. JPMorgan Chase & Co. boosted their price target on Edwards Lifesciences from $72.00 to $78.00 and gave the stock a “neutral” rating in a report on Friday, October 25th. Canaccord Genuity Group boosted their price target on Edwards Lifesciences from $63.00 to $68.00 and gave the stock a “hold” rating in a report on Thursday, December 5th. Barclays boosted their price target on Edwards Lifesciences from $85.00 to $88.00 and gave the stock an “overweight” rating in a report on Monday, December 2nd. Finally, Stifel Nicolaus raised Edwards Lifesciences from a “hold” rating to a “buy” rating and boosted their price target for the stock from $75.00 to $90.00 in a report on Thursday, January 30th. One analyst has rated the stock with a sell rating, fourteen have issued a hold rating and twelve have issued a buy rating to the company’s stock. According to data from MarketBeat, the company presently has a consensus rating of “Hold” and an average target price of $79.19.

Edwards Lifesciences Price Performance

Shares of EW stock opened at $70.38 on Monday. Edwards Lifesciences Co. has a 12-month low of $58.93 and a 12-month high of $96.12. The firm has a market capitalization of $41.51 billion, a price-to-earnings ratio of 10.16, a price-to-earnings-growth ratio of 3.64 and a beta of 1.10. The company has a quick ratio of 2.89, a current ratio of 3.46 and a debt-to-equity ratio of 0.06. The firm has a fifty day moving average of $72.45 and a 200-day moving average of $69.30.

Edwards Lifesciences Profile

Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL PRECISION and Cardioband names.